ACRV - Acrivon Therapeutics, Inc. Common Stock News

Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At A

Presentations and DetailsOral Podium PresentationTitle: Acrivon Predictive Precision Proteomics (AP3

Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and

Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1

seekingalpha.com

Acrivon Therapeutics: Priced For Failure, Built For Precision

Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform

Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit

WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon

Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the ana

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinic

The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous inter

Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a cl

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and AC

Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acriv

Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% – Still a Buy?

Shares of Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) were up 3.2% on Monday. The st

Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV)

Acrivon Therapeutics (NASDAQ: ACRV - Get Free Report) and Oasmia Pharmaceutical (OTCMKTS:OASMY - Get

Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the ana

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business

Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overa

Acrivon Therapeutics To Reveal Pre-Clinical AP3 Data At The 2026 AACR Annual Meeting

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical syn

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Stro

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical syn

zacks.com

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why

Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Canc

Acrivon Therapeutics (NASDAQ: ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focu

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivo

Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the

Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Int

Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to cond

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update

Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) saw a large decrease in short interest i

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynec

Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farbe

Acrivon Therapeutics (NASDAQ:ACRV) CFO Acquires $15,014.40 in Stock

Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) CFO Adam Levy purchased 8,832 shares of

Acrivon Therapeutics (NASDAQ:ACRV) CEO Acquires $82,320.00 in Stock

Acrivon Therapeutics, Inc. (NASDAQ: ACRV - Get Free Report) CEO Peter Blume-Jensen purchased 49,000

12 Health Care Stocks Moving In Thursday's Intraday Session

Market-Moving News for January 8th

ACON: 54% | Aclarion Reports Triple-Digit Growth for AI Back Pain Platform as Nociscan Adoption Acce

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session